The TRUTH is that in the Phase 2a trial using Blarcamesine to treat mile to moderate participants with baseline MMSE scores of 16 to 28 inclusive, the vast majority of participants did better than those on the SOC (standard of care). That is a FACT!!!
The BLACK solid and dotted shows the response to the SOC (standard of care).
Market Data 
Markets 
AI
